(MedPage Today) — The FDA issued a warning letter to Novo Nordisk for failing to report and investigate potentially serious side effects associated with its popular GLP-1 medications.
In a letter dated March 5 and made public on Tuesday, the…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.






